secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-12-05T23:59:59+00:00
Accession:  0001213900-25-118699
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio: Phase 2 XPro1595 neuroimaging slows neurodegeneration in high-inflammation AD; MSC therapy review published
--------------------------------------------------------------------------------

- New PerpPD+ MRI imaging from Phase 2 MINDFuL trial shows trend toward slowed cortical disarray progression in early AD patients with high neuroinflammation (ADi).
- Data presented at CTAD conference; reinforces prior directional improvements on cognitive, biomarker, and neuropsychiatric endpoints.
- Additional MRI analyses from MINDFuL trial expected in 2026 to assess gray- and white-matter integrity.
- INmune Bio publishes peer-reviewed article on MSC therapies, including CORDStrom platform; BLA/MAA filing for RDEB expected in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025118699/0001213900-25-118699-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025118699/ea0268534-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-118699

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer